Over the past four decades, the global incidence of MM has demonstrated an increasing trend (albeit with variability across different regions and time periods) [ 3 , 4 , 5 , 6 ].
← all excerpts
Synergistic Antitumor Activity of HAT Inhibitor A485 and XPO1 Inhibitor KPT8602 in Multiple Myeloma.
1
—
—